Dr. Lucy Vereshchagina is executive vice president of science and regulatory advocacy at the Pharmaceutical Research and Manufacturers of America (PhRMA). In this role, Lucy leads PhRMA’s science and regulatory advocacy department supporting PhRMA’s policy, advocacy, and science priorities, as well as global regulatory advocacy efforts, including the International Council for Harmonization (ICH). Dr. Vereshchagina was the lead PhRMA negotiator for both PDUFA VII and BsUFA III and testified before Congress on the agreements’ reauthorization. Prior to joining PhRMA in 2012, Dr. Vereshchagina spent over 12 years with the FDA & Healthcare Practice at an international law firm and the Investigational Drug Branch at the National Cancer Institute, NIH. Lucy has Master’s degrees in Biochemistry and Chemistry, earned her Ph.D. in Chemistry at the Catholic University of America, and completed her post-doctoral studies in molecular biology and immunology at the Walter Reed Army Institute of Research.